Physician profile
Mark David Callery
NPI 1548246895
$2,567.67
in general payments reported to CMS, 2019-2025
37 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $220 · 2021: $23.58 · 2022: $467 · 2023: $497 · 2024: $336 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $253.39 | 2019-2025 | |
| Abbott Laboratories | $218.68 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $169.67 | 2019-2023 | Verquvo, Belsomra, Dificid |
| Pfizer INC. | $148.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.18 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $143.60 | 2019-2024 | Veozah |
| Amgen INC. | $123.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $72.95 | 2019-2025 | Spravato |
| Lilly USA, LLC | $68.90 | 2020-2023 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $59.99 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.70 | 2023 | Trulance, Xifaxan |
| Insulet Corporation | $51.37 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $46.52 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $46.09 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $44.04 | 2020-2022 | |
| Dexcom, INC. | $40.87 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $33.13 | 2022 | |
| Corium, LLC | $31.20 | 2024 | Azstarys |
| Arbor Pharmaceuticals, INC. | $31.17 | 2019 | |
| Therapeuticsmd, INC. | $28.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.25 | 2020 | |
| Fisher & Paykel Healthcare INC | $24.13 | 2025 | Fisher & Paykel Healthcare |
| Celgene Corporation | $20.72 | 2019 | |
| Gilead Sciences, INC. | $20.64 | 2019 | |
| Roche Diagnostics Corporation | $20.57 | 2019 | |
| Eisai INC. | $19.31 | 2025 | |
| Krystal Biotech INC | $18.66 | 2025 | Vyjuvek |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.42 | 2023 | Quviviq |
| Avion Pharmaceuticals | $14.86 | 2019 | |
| Currax Pharmaceuticals LLC | $14.83 | 2024 | Contrave |
| Optinose US, INC. | $14.34 | 2019 | |
| Irhythm Technologies, INC. | $14.11 | 2024 | Zio Xt Patch, Zio Monitor |
| Allergan, INC. | $14.11 | 2019 | |
| Circassia INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Callery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.